CEO Executive AssistantScience advisory board pharma CEO management is one of the most underutilized governance tools in pharmaceutical leadership. Many pharma and biotech companies have science advisory boards that function primarily as credentialing exercises: a roster of distinguished names on a website, two meetings per year with presentations from internal teams, and recommendations that rarely create visible impact on program decisions.
The companies where science advisory boards actually work – where advisors provide the kind of frank, expert input that changes decisions and prevents expensive mistakes – have built them differently. The CEO’s personal engagement, the quality of the questions asked, and the organizational follow-through on advisory input are the three variables that separate high-value SABs from performative ones.
Why Science Advisory Boards Fail
Before addressing how to build a productive SAB, understand the failure modes:
Wrong composition: SAB members selected for name recognition rather than specific expertise relevant to your current pipeline questions. A Nobel laureate in biochemistry is not necessarily the right advisor for your oncology clinical strategy.
Wrong format: SAB meetings structured as company presentations rather than genuine scientific discussions. Advisors learn about your programs rather than engaging with the hard questions you face.
Wrong questions: Management presents updates without asking the specific, consequential questions where external expert input would change decisions.
No follow-through: Advisory recommendations are received, thanked, and then rarely visible in subsequent program decisions. Advisors notice this and calibrate their future engagement accordingly.
Wrong CEO engagement: CEO absent from substantive SAB discussions, present only for opening remarks, leaving advisors uncertain whether their input will reach the executive level.
Each of these failures is correctable. The CEO is the one person in the organization with the authority and the incentive to correct all of them simultaneously.
Building the Right SAB Composition
The composition question starts with a frank assessment: what are the most important scientific questions facing your pipeline over the next 24 to 36 months? For a precision oncology company, you might need expertise in tumor immunology, biomarker-driven trial design, and clinical development in the specific cancer subtypes you are targeting. For a gene therapy company, you need vector biology expertise, manufacturing science, and long-term follow-up design experience.
Build your SAB composition around these specific expertise requirements, not around building an impressive roster. A smaller SAB of eight to twelve members with precisely matched expertise will provide better input than a larger group with more general scientific distinction.
Diversity of perspective matters: include both basic scientists and clinicians, both academic and industry-experienced advisors, and international experts where your development program has global regulatory implications. One or two members with direct FDA or EMA experience (not current government employees, but former officials or those who have been deeply involved in regulatory science) add significant value when regulatory strategy questions arise.
Advisors should have no material conflicts with your current programs. Compensating SAB members appropriately and transparently – consistent with fair market value for their expertise – is both compliant and respectful of their time.
Designing SAB Meetings That Generate Real Input
The single most important design decision is the ratio of presentation time to discussion time. Most SAB meetings invert the productive ratio: 70 percent presentations, 30 percent discussion. The target should be closer to 40 percent presentations and 60 percent structured discussion.
Achieve this by:
Sending pre-read materials two to three weeks before the meeting: Advisors should arrive already familiar with the program background. Meeting time is then available for discussion rather than briefing.
Organizing sessions around specific decisions, not program updates: Instead of “update on Program X,” frame sessions as “We are deciding between Design A and Design B for our Phase III. What is your assessment of the trade-offs?” This framing demands specific input rather than general reaction.
Ending each session with explicit advisory recommendations: The SAB chair or CEO should summarize what they heard and what they will do about it before moving to the next session. This creates accountability for follow-through and signals to advisors that their input is being captured.
Reserving time for executive session without management present: Advisors who can discuss their observations privately – without company employees in the room – often provide more candid collective input than they will in the full group setting. Use this session to understand what advisors collectively believe the company is doing well and poorly.
The CEO’s Role in SAB Sessions
Your participation in SAB sessions should not be ceremonial. Come prepared on the substance, stay for the scientific discussions that matter to current decisions, and be seen to take specific advisory input seriously.
Before each SAB meeting, your CMO and CSO should prepare you with a one-page brief on the top three questions you want answered. These are not management presentation topics; they are the hard questions you are genuinely uncertain about. Which endpoint definition gives us the best chance of approval and payer acceptance? Are we being too conservative in our patient selection biomarker? Is our Phase II data sufficient to proceed to pivotal development?
In the SAB sessions, practice the discipline of asking your questions and listening to the answers rather than defending your current decisions. The advisors who have been around for multiple SAB meetings know when a CEO is listening versus when they are validating. Only one of these builds a high-quality advisory relationship.
An annual candid conversation with your SAB chair – outside the formal meeting structure – is a valuable investment. Ask them directly: Are we using this board well? What questions should we be asking that we are not? Who on the SAB should we be engaging more and on what topics?
Connecting SAB Input to Pipeline Decisions
The most common SAB failure mode is excellent advice that does not visibly influence program decisions. When this pattern persists, the best advisors disengage over time.
Build an explicit SAB input tracking process: after each meeting, your CMO documents the specific recommendations from the SAB, the decision each recommendation informs, the timeline for that decision, and the outcome. At the following SAB meeting, open with a summary of how advisory input from the previous meeting was incorporated into decisions.
This tracking process serves two purposes: it creates organizational accountability for actually using advisory input, and it demonstrates to advisors that their time investment has tangible impact. Both effects are necessary for a high-functioning SAB.
The connection between SAB input and your regular pipeline review cadence should be explicit. SAB sessions that precede key pipeline decision points – phase transitions, go/no-go decisions, strategic pivots – are the highest-leverage use of advisory engagement.
Using the SAB Beyond Formal Meetings
The formal SAB meeting is not the only way to leverage your advisory board. Between meetings:
Ad hoc consultations on specific questions: When a specific program question arises – an unexpected safety signal, an FDA question requiring technical expertise, a competitive development that changes your landscape – an individual SAB member with relevant expertise can provide targeted input through a brief consulting engagement. Your CMO manages this through the normal advisory engagement process.
Regulatory interaction support: SAB members with regulatory expertise can review pre-submission materials, help prepare for FDA advisory committee meetings, or provide strategic advice on responding to agency questions. This targeted use of expert capacity is often more valuable than formal meeting presentations.
External representation: SAB members who present at scientific conferences, publish in peer-reviewed journals, and participate in industry advisory committees represent your company’s scientific thinking indirectly. When they are genuinely engaged with your science, their external voice adds credibility that formal company communications cannot match.
The CEO’s Relationship With SAB Chairs
Your SAB chair is the most important advisory relationship to invest in personally. The chair sets the tone for the entire board, manages the quality of scientific discussion, and is your primary source of candid feedback on how the company is using the advisory board.
Invest in this relationship beyond formal meetings. A quarterly phone call of 30 to 45 minutes with your SAB chair – covering your current program priorities, the key decisions coming in the next two quarters, and any concerns about your development program – keeps the chair engaged and informed between meetings. It also provides you with a trusted scientific perspective on questions that may not be mature enough for full SAB discussion.
CEOs who treat the SAB chair as a governance requirement rather than a genuine scientific partnership are missing the most valuable dimension of the advisory board relationship. Build it with the same intentionality you would bring to your most important board reporting pharma relationships.
Conclusion
Science advisory board pharma CEO management is one of those leadership activities where the gap between how it is commonly done and how it could be done is enormous. The executives who build SABs that actually change program decisions – through careful composition, substantive meeting design, active CEO participation, and rigorous follow-through – have a scientific governance advantage that shows up in clinical program quality and regulatory outcomes. The time investment is modest: two to four SAB days per year plus the preparation and follow-through that makes those days valuable. The return, measured in avoided development mistakes and accelerated program decisions, is substantial.
Related Reading
For further context, explore Pharma CEO Time Management for Autoimmune Disease Strategy and Biomarker-Driven Trial Management: What Pharma CEOs Must Decide and When.